Lotronex Advisory Committee Will Discuss Program For Ischemic Colitis Risk

A risk management program to track postmarketing incidences of ischemic colitis with Glaxo Wellcome's Lotronex will be discussed at the June 27 meeting of FDA's Gastrointestinal Drugs Advisory Committee.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet